Please login to the form below

Not currently logged in
Email:
Password:

Basilea's Hans Christian Rohde takes up commercial role at uniQure

Will serve as gene therapy specialist's chief commercial officer

uniQure Hans Christian RohdeGene therapy company uniQure has appointed Hans Christian Rohde to serve as its new chief commercial officer.

Rohde joins the company from Basilea Pharmaceutica, where he was chief commercial officer and a member of that company's executive management committee.

In his new role at Netherlands-based uniQure he will be tasked with helping the company commercialise Glybera, which last month became the first gene therapy to be approved in the western world.

Glybera treats patients with the inherited disease lipoprotein lipase deficiency (LPLD), which is also known as familial hyperchylomicronemia and is extremely rare, affecting no more than 1-2 people per million.

Jörn Aldag, CEO of uniQure, said: “With the approval of Glybera we need to rapidly build and expand our commercial organisation to enable the successful roll-out of Glybera and provide access to this crucial treatment to as many patients as possible.

“Hans Christian's experience and successful track-record in major biotechnology companies such as Basilea, Merck-Serono and Biogen Idec provide us with the necessary leadership qualities to successfully commercialise Glybera.”

Rohde has almost 25 years experience in commercial roles across the pharma and biotech industries.

Prior to Basilea, he was corporate vice president, head of global therapeutic areas, reproductive health and endocrinology at Merck-Serono from 2003 until 2007.

Before this he was responsible for international marketing and global market development at Biogen Idec.

7th December 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics